Mohamed Abdelkawy

Spectrophotometric Determination of Ibuprofen via its Copper (II) Complex

Abstract A rapid, sensitive and specific procedure for determination of ibuprofen has been developed. The drug solution in chloroform is treated with Cu(II) solution at pH 5.5, forming a blue compound which is extractable in the organic phase. This complex is spectrophotometrically measured at λ 675 nm obeying Beers Law in a concentration range of 0.5 — 3.2 mg.ml-1. Accurate and precise results are obtained with mean percentage recovery of 100.13 ± 1.25. The obtained complex has an apparent molar absorptivity of 0.48 × 102 and bears no interference from other metal ions. The stoichiometry of the reaction was studied and the reaction product was isolated for further studies. The procedure has been successfully carried out for analysis of Brufen tablets and its validity was checked by applying the standard addition technique.

Spectrophotometric and spectrodensitometric determination of Clopidogrel Bisulfate with kinetic study of its alkaline degradation

Four sensitive, selective and precise stability-indicating methods for the determination of Clopidogrel Bisulfate (CLP) in presence of its alkaline degradate and in pharmaceutical formulations were developed and validated. Method A is a second derivative (D(2)) spectrophotometric one, which allows the determination of CLP in presence of its alkaline degradate at 219.6, 270.6, 274.2 and 278.4 nm (corresponding to zero-crossing of the degradate) over a concentration range of 4-37 microg mL(-1) with mean percentage recoveries 99.81+/-0.893, 99.72+/-0.668, 99.88+/-0.526 and 100.46+/-0.646, respectively. CLP can be determined in the presence of up to 65% of its degradate. D(2) method was used to study the kinetic of CLP alkaline degradation that was found to follow a first-order reaction. The t(1/2) was 6.42 h while K (reaction rate constant) was 0.1080 mol/h. Method B is the first derivative of the ratio spectra (DD(1)) spectrophotometric method, by measuring the peak amplitude at 217.6 and 229.4 nm using acetonitrile and CLP can be determined in the presence of up to 70% of its degradate. The linearity range was 5-38 microg mL(-1) with mean percentage recoveries 99.88+/-0.909 and 99.70+/-0.952, respectively. Method C based on the determination of CLP by the bivariate calibration depending on simple mathematic algorithm which provides simplicity and rapidity. The method depends on quantitative evaluation of the absorbance at 210 and 225 nm over a concentration range 5-38 microg mL(-1) with mean percentage recovery 99.27+/-1.115. CLP can be determined in the presence of up to 70% of its degradate. Method D is a TLC-densitometric one, where CLP was separated from its degradate on silica gel plates using hexane:methanol:ethyl acetate (8.7:1:0.3, v/v/v) as a developing system. This method depends on quantitative densitometric evaluation of thin layer chromatogram of CLP at 248 nm over a concentration range of 0.6-3 microg/band with mean percentage recovery 99.97+/-1.161. CLP can be determined in the presence of up to 90% of its alkaline degradate. The selectivity of the proposed methods was checked using laboratory prepared mixtures. The proposed methods have been successfully applied to the analysis of CLP in pharmaceutical dosage forms without interference from other dosage form additives and the results were statistically compared with the official method.

Simultaneous determination of olanzapine and fluoxetine hydrochloride in capsules by spectrophotometry, TLC-spectrodensitometry and HPLC

This paper describes sensitive, accurate and precise spectrophotometric, TLC-spectrodensitometric and high performance liquid chromatographic (HPLC) methods for simultaneous determination of olanzapine and fluoxetine HCl. Two spectrophotometric methods were developed, namely; first derivative (D1) and derivative ratio (DD1) methods. The TLC method employed aluminum TLC plates precoated with silica gel GF254 as the stationary phase and methanol:toluene:ammonia (7:3:0.1, by volume) as the mobile phase, where the chromatogram was scanned at 235 nm. The developed HPLC method used a reversed phase C18 column with isocratic elution. The mobile phase composed of phosphate buffer pH 4.0:acetonitrile:triethylamine (53:47:0.03, by volume) at flow rate of 1.0 mL min−1. Quantitation was achieved with UV detection at 235 nm. The methods were validated according to the International Conference on Harmonization (ICH) guidelines. The selectivity of the proposed methods was tested using laboratory-prepared mixtures. The developed methods were successfully applied for the determination of olanzapine and fluoxetine HCl in bulk powder and combined capsule dosage form.

Validated stability indicating methods for determination of nitazoxanide in presence of its degradation products

Three sensitive, selective and reproducible stability-indicating methods are presented for determination of nitazoxanide (NTZ), a new anti-protozoal drug, in presence of its degradation products. Method A utilizes the first derivative of ratio spectra spectrophotometry by measurement of the amplitude at 364.4 nm using one of the degradation products as a divisor. Method B is a chemometric-assisted spectrophotometry, where principal component regression (PCR) and partial least squares (PLS) were applied. These two approaches were successfully applied to quantify NTZ in presence of degradation products using the information included in the absorption spectra in the range 260–360 nm. Method C is based on the separation of NTZ from its degradation products followed by densitometric measurement of the bands at 254 nm. The separation was carried out on silica gel 60F254, using chloroform–methanol–ammonia solution–glacial acetic acid (95:5:1:1 by volume, pH=5.80) as a developing system. These methods are suitable as stability-indicating methods for the determination of NTZ in presence of its degradation products either in bulk powder or in pharmaceutical formulations. Statistical analysis of the results has been carried out revealing high accuracy and good precision.

Spectrophotometric determination of isopropamide Iodide and trifluoperazine hydrochloride in presence of trifluoperazine oxidative degradate

Four sensitive, selective and precise stability indicating methods for the determination of isopropamide iodide (ISO) and trifluoperazine hydrochloride (TPZ) in their binary mixture and in presence of trifluoperazine oxidative degradate (OXD). Method A is a derivative spectrophotometric one, where ISO was determined by first derivative (D(1)) at 226.4 nm while TPZ was determined by second derivative (D(2)) at 270.2 nm. Method B is the first derivative of the ratio spectra (DD(1)) spectrophotometric method, ISO can be determined by measuring the peak amplitude at 227.4 nm using 5 microg mL(-1) of OXD as a divisor, while TPZ can be determined by measuring the peak amplitude at 249.2 and 261.4 nm using 15 microg mL(-1) of ISO as a divisor. Method C is the isoabsorptive spectrophotometric method. This method allows determination of ISO and TPZ in their binary mixture by measuring total concentration of ISO and TPZ at their isoabsorptive point at lambda(229.8) nm (Aiso1) while TPZ concentration alone can be determined at lambda(max) 311.2 nm, then ISO concentration can be determined by subtraction. On the same basis TPZ can be determined in presence of ISO and OXD, where OXD concentration alone was determined by measuring the peak amplitude at lambda(281.6) and lambda(309.4) nm while total concentration of TPZ and OXD was determined at their isoabsorptive points at (Aiso2 = 270.2 nm), (Aiso3 = 310.6 nm) and (Aiso4 = 331.8 nm) then TPZ concentration was determined by subtraction. Method D is the multivariate calibration techniques [the classical least squares (CLS), principal component regression (PCR) and partial least squares (PLS)], using the information contained in the absorption spectra of ISO, TPZ and OXD mixtures. The selectivity of the proposed methods was checked using laboratory prepared mixtures. The proposed methods have been successfully applied to the analysis of ISO and TPZ in pharmaceutical dosage form without interference from other dosage form additives and the results were statistically compared with the reported method.

Simultaneous determination of methocarbamol and ibuprofen or diclofenac potassium using mean centering of the ratio spectra method

Simultaneous determination of methocarbamol and ibuprofen or diclofenac potassium using mean centering of the ratio spectra method Accurate and sensitive methods were developed for simultaneous determination of methocarbamol and ibuprofen or diclofenac potassium in their binary mixtures, and in the presence of a methocarbamol related substance (guaifenesin) using mean centering of the ratio spectra method. The results obtained were statistically compared with the reported HPLC methods; no significant difference between the proposed methods and the reported methods was found regarding either accuracy or precision. Simultano određivanje metokarbamola i ibuprofena ili diklofenak kalija metodom centriranja srednjih vrijednosti spektralnih omjera (mean centering of the ratio spectra method) U radu su opisane točne i osjetljive metode za simultano određivanje metokarbamola i ibuprofena ili diklofenak kalija u njihovim binarnim smjesama, te u prisutnosti gvajfenezina, supstancije srodne metokarbamolu koristeći metodu centriranja srednjih vrijednosti spektralnih omjera. Dobiveni rezultati su statistički uspoređeni s objavljenim HPLC metodama. Nije pronađena značajna razlika u točnosti i preciznosti između predložene metode i objavljenih metoda.

Stability-Indicating Chromatographic Methods for the Determination of Sertindole

In this work, two chromatographic methods have been developed and validated for the determination of sertindole (an antipsychotic agent) in the presence of its oxidative degradation product. Sertindole was subjected to stress stability studies, including acid, alkali, oxidative, photolytic and thermal degradation. The chromatographic methods included the use of thin-layer chromatography (TLC-densitometry) and high-performance liquid chromatography (HPLC). The TLC method employed aluminum TLC plates precoated with silica gel G.F254 as the stationary phase and methanol-ethyl acetate-33% ammonia (1:9:0.1, by volume) as the mobile phase, and the chromatograms were scanned at 227 nm. The developed HPLC method used a reversed-phase C18 column with isocratic elution. The mobile phase was composed of phosphate buffer pH 3.0-acetonitrile-triethylamine (45:55:0.03, by volume) and run at a flow rate of 1.0 mL/min. Quantitation was achieved with ultraviolet detection at 256 nm. The linearity ranges were found to be 2-14 µg/band and 5-200 µg/mL for TLC and HPLC, respectively. The developed methods were validated according to the International Conference on Harmonization guidelines and were applied for bulk powder and dosage forms.

Validated Stability Indicating RP-HPLC for Quantitation of Nitazoxanide in Presence of Its Alkaline Degradation Products and Their Characterization by HPLC-Tandem Mass Spectrometry

A simple and sensitive stability indicating HPLC method was developed and validated for quantitative determination of Nitazoxanide (NTZ), a new antiprotozoal drug, in presence of degradation products generated under forced alkaline hydrolysis. Chromatographic separation was achieved on Inertsil C8-3 column (150 × 4.6 mm i.d.) using a mobile phase composed of acetonitrile: 50 mM ammonium acetate buffer (50:50, v/v, pH 5.0 adjusted with acetic acid) at a flow rate of 1 mL/min. Quantification was achieved with UV detection at 298 nm based on relative peak area. The method was linear over the concentration range of 0.8-50 µg/mL (r = 0.9999) with a limit of detection and quantification 0.0410 and 0.1242 µg/mL, respectively. The developed method has the requisite accuracy, selectivity, sensitivity and precision to assay NTZ in presence of its degradation products either in bulk powder or in pharmaceutical formulations. The degradation products were then identified by HPLC-MS/MS analysis using an electrospray ionization source and an ion trap analyzer.

Spectrofluorimetric determination of 3-methylflavone-8-carboxylic acid, the main active metabolite of flavoxate hydrochloride in human urine.

A simple, sensitive and selective spectrofluorimetric method has been developed for the determination of 3-methylflavone-8-carboxylic acid as the main active metabolite of flavoxate hydrochloride in human urine. The proposed method was based on the measurement of the native fluorescence of the metabolite in methanol at an emission wavelength 390 nm, upon excitation at 338 nm. Moreover, the urinary excretion pattern has been calculated using the proposed method. Taking the advantage that 3-methylflavone-8-carboxylic acid is also the alkaline degradate, the proposed method was applied to in vitro determination of flavoxate hydrochloride in tablets dosage form via the measurement of its corresponding degradate. The method was validated in accordance with the ICH requirements and statistically compared to the official method with no significant difference in performance.

Simultaneous Determination of Thalidomide and Dexamethasone in Rat Plasma by Validated HPLC and HPTLC With Pharmacokinetic Study

Two validated chromatographic methods have been developed for the simultaneous determination of thalidomide (THD) and dexamethasone (DEX) in rat plasma using paracetamol (PAR) as an internal standard (IS). Chromatographic analysis was achieved firstly by HPLC method on C18 column (150 × 4.6 mm2 i.d., 5 μm) and a mobile phase composed of ethanol:water (containing 0.1% acetic acid) (70:30, v/v) at the flow rate of 0.6 mL min-1. The second method was HPTLC method which depended on using a developing system of methylene chloride:acetone:ethyl acetate (7:4:1, by volume). In both methods, PAR was used as an IS. The developed methods have been validated as per FDA guidelines. All parameters were tested using quality control samples (LQC, MQC and HQC). All the obtained parameters were within the acceptance criteria. In the same way, the two methods were successfully used to study the pharmacokinetic parameters of both THD and DEX after their intra-peritoneal administration. Moreover, results obtained after administration of each drug alone were compared to those obtained after their administration together. The drugs showed drug-drug interactions when administered in combination, meaning that monitoring of such combination is very important.